CO6220935A2 - Derivados de 1,2,4-triazol como moduladores de mglur5 - Google Patents

Derivados de 1,2,4-triazol como moduladores de mglur5

Info

Publication number
CO6220935A2
CO6220935A2 CO09043380A CO09043380A CO6220935A2 CO 6220935 A2 CO6220935 A2 CO 6220935A2 CO 09043380 A CO09043380 A CO 09043380A CO 09043380 A CO09043380 A CO 09043380A CO 6220935 A2 CO6220935 A2 CO 6220935A2
Authority
CO
Colombia
Prior art keywords
group
alkyl
hydrogen
mglur5
modulators
Prior art date
Application number
CO09043380A
Other languages
English (en)
Spanish (es)
Inventor
Methvin Isaac
Abdelmalik Slassi
Louise Edwards
Peter Dove
Tao Xin
Tomislav Stefanac
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6220935(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6220935A2 publication Critical patent/CO6220935A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
CO09043380A 2006-10-05 2009-04-29 Derivados de 1,2,4-triazol como moduladores de mglur5 CO6220935A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82832506P 2006-10-05 2006-10-05

Publications (1)

Publication Number Publication Date
CO6220935A2 true CO6220935A2 (es) 2010-11-19

Family

ID=39032082

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09043380A CO6220935A2 (es) 2006-10-05 2009-04-29 Derivados de 1,2,4-triazol como moduladores de mglur5

Country Status (21)

Country Link
US (1) US7772235B2 (enExample)
EP (1) EP2079730A1 (enExample)
JP (1) JP2010505809A (enExample)
KR (1) KR20090060328A (enExample)
CN (1) CN101547916A (enExample)
AR (1) AR062965A1 (enExample)
AU (1) AU2007303889B2 (enExample)
BR (1) BRPI0719155A2 (enExample)
CA (1) CA2665083A1 (enExample)
CL (1) CL2007002757A1 (enExample)
CO (1) CO6220935A2 (enExample)
IL (1) IL197722A0 (enExample)
MX (1) MX2009003227A (enExample)
NO (1) NO20091626L (enExample)
NZ (1) NZ575657A (enExample)
PE (1) PE20081378A1 (enExample)
RU (1) RU2439068C2 (enExample)
SA (1) SA07280518B1 (enExample)
TW (1) TW200821305A (enExample)
UY (1) UY30610A1 (enExample)
WO (1) WO2008041075A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
TW200922586A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054786A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
TW200922585A (en) * 2007-10-26 2009-06-01 Astrazeneca Ab Amino 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054787A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
TW201011016A (en) * 2008-08-12 2010-03-16 Astrazeneca Ab New compounds 501
UY32044A (es) * 2008-08-12 2010-03-26 Astrazeneca Ab Nueva forma cristalina a de 4-(5-{ (1r)-1-[5-(3-clorofenil)isoxazol-3-il]etoxi} -4-metil-4h-1,2,4-triazol-3-il)piridina
SG171755A1 (en) * 2008-12-18 2011-07-28 Astrazeneca Ab New process for the preparation of 1- [5- (3-chloro-phenyl) - isooxazol-3-yl] -ethanone and (r) -1- [5- (3-chloro-phenyl) - isooxazol-3-yl] -ethanol
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
IN2012DN03322A (enExample) * 2009-09-21 2015-10-23 Univ Vanderbilt
WO2012058128A2 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Caprolactam mglur5 receptor modulators
EP2648723A4 (en) 2010-12-08 2014-04-02 Univ Vanderbilt Bicyclic pyrazole compounds as allergic Mglur5 receptor modulators
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
EP2857387A1 (en) 2013-10-07 2015-04-08 Boehringer Ingelheim International Gmbh Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid
CN109311823B (zh) * 2016-07-15 2023-01-24 泸州东方农化有限公司 一种1,2,4-三唑-3-硫酮化合物的合成方法及其中间体
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894241A (zh) * 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0514296D0 (en) 2005-07-12 2005-08-17 Novartis Ag Organic compounds
AR058807A1 (es) * 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
TW200811157A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V

Also Published As

Publication number Publication date
AU2007303889A1 (en) 2008-04-10
AU2007303889B2 (en) 2011-02-24
SA07280518B1 (ar) 2011-01-15
RU2009111113A (ru) 2010-11-10
PE20081378A1 (es) 2008-11-12
TW200821305A (en) 2008-05-16
MX2009003227A (es) 2009-04-06
RU2439068C2 (ru) 2012-01-10
IL197722A0 (en) 2009-12-24
BRPI0719155A2 (pt) 2014-02-04
EP2079730A1 (en) 2009-07-22
US20080125436A1 (en) 2008-05-29
CL2007002757A1 (es) 2008-06-20
CN101547916A (zh) 2009-09-30
AU2007303889A2 (en) 2010-07-15
AR062965A1 (es) 2008-12-17
WO2008041075A1 (en) 2008-04-10
KR20090060328A (ko) 2009-06-11
US7772235B2 (en) 2010-08-10
NZ575657A (en) 2011-03-31
UY30610A1 (es) 2008-05-02
JP2010505809A (ja) 2010-02-25
CA2665083A1 (en) 2008-04-10
NO20091626L (no) 2009-05-04

Similar Documents

Publication Publication Date Title
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
ES2564782T3 (es) Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos
AR060813A1 (es) Moduladores de mglur5 iii
CO6251247A2 (es) Imidazoquinolinas con propiedades inmuno-moduladoras
AR060812A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
NI201000059A (es) Inhibidores de la cinasa c-fms.
EA201170096A1 (ru) Замещенные производные пиримидона
TNSN07348A1 (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
CO6220907A2 (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
ATE443701T1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
CR10346A (es) Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
CO6220851A2 (es) Compuestos de ciclohexandiona sustituidos en la posicion 5
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
CY1111428T1 (el) Μεθοδος για τη συνθεση της 5-(μεθυλ-1η-ιμιδαζολ-1-υλο)-3-(τριφθορομεθυλο)-βενζολαμινης
AR079498A1 (es) Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a
AR074481A1 (es) Derivados de tienopiridina como inhibidores de quinasa
MX2010007593A (es) Derivados novedosos de acil cianopirrolidinas.
AR060810A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
CO6351693A2 (es) Nuevos derivados de acilamonobenzamida

Legal Events

Date Code Title Description
FC Application refused